Patents by Inventor Heidemarie Kletzl

Heidemarie Kletzl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NEW TREATMENT OF SMA
    Publication number: 20230338382
    Abstract: The present invention relates to 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one for use in the treatment of spinal muscular atrophy (SMA), its pharmaceutical composition to be used in the treatment of SMA, its methods of treatment thereof.
    Type: Application
    Filed: December 5, 2022
    Publication date: October 26, 2023
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Jean-Paul Pfefen, Heidemarie Kletzl, Lutz Mueller
  • Treatment of SMA
    Patent number: 11534444
    Abstract: The present invention relates to 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one for use in the treatment of spinal muscular atrophy (SMA), its pharmaceutical composition to be used in the treatment of SMA, its methods of treatment thereof.
    Type: Grant
    Filed: April 2, 2020
    Date of Patent: December 27, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Jean-Paul Pfefen, Heidemarie Kletzl, Lutz Mueller
  • TREATMENT OF SMA
    Publication number: 20220168307
    Abstract: The present invention relates to 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one for use in the treatment of spinal muscular atrophy (SMA), its pharmaceutical composition to be used in the treatment of SMA, its methods of treatment thereof.
    Type: Application
    Filed: December 10, 2021
    Publication date: June 2, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventor: Heidemarie Kletzl
  • NEW TREATMENT OF SMA
    Publication number: 20200375993
    Abstract: The present invention relates to 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one for use in the treatment of spinal muscular atrophy (SMA), its pharmaceutical composition to be used in the treatment of SMA, its methods of treatment thereof.
    Type: Application
    Filed: April 2, 2020
    Publication date: December 3, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Jean-Paul Pfefen, Heidemarie Kletzl, Lutz Mueller